Home | Services & Solutions | Drug Product | Oral | Pre-formulation

The unsatisfactory physicochemical properties of drug molecules can lead to problems such as low solubility, permeability, and bioavailability, as well as high toxicity, poor efficacy, and manufacturing challenges. These issues can result in the abandonment of numerous molecules and increased clinical failure rates. Our pre-formulation studies assist in selecting the most developable molecules at the preclinical stage. We develop suitable preclinical formulations to support pharmacokinetic (PK), pharmacodynamic (PD), and toxicology studies in animals. Moreover, we determine formulation strategies to aid in clinical formulation development and manufacturing.

Our pre-formulation labs are located at the Shanghai Waigaoqiao site and the Wuxi City site, each staffed with dedicated teams of formulation and analytical scientists. 

What we can deliver:

Service Roadmap



Physical Form


Enabling Formulation
In Silico
IND Enabling Preformulation Package (IEPP)

IEPP is an integrated developability assessment service for new chemical entities (NCEs) to efficiently identify challenges and provide solutions earlier for increasing success rate and lower overall costs. It usually takes 8-12 weeks for IND ready formulation.

Platform Capabilities: Within 8-12 weeks, the most developable molecule with the optimal formulation strategy is ready for IND filing. Not limited to the small molecules (both conventional and high potency compound), also including formulation screening and selection for new modality, like PROTAC, peptide, oligonucleotide.

Why choose IEPP of WuXi STA?

Related Resources

Scroll to Top
Please enable JavaScript in your browser to complete this form.